Stefan Nowicki

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Ben Fulton, Susan Short, Allan James et al. · Clinical and Translational Radiation Oncology · 2017 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

Anthony J. Chalmers, Susan Short, Colin Watts et al. · Journal of Clinical Oncology · 2018 · 36 citations

Medicine, Oncology, Pharmacology +17

A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime

Mario Teo, Sean Martin, Kevin Agyemang et al. · British Journal of Neurosurgery · 2013 · 27 citations

Medicine, Oncology, Surgery +16

Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial

Sarah Derby, Mark R. Jackson, Karin Williams et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

Evert S.M. van Aken, Bharti Devnani, Arsela Prelaj et al. · Annals of Oncology · 2025 · 11 citations · Full text

Medicine, Oncology, Radiation Oncology +17